Efirel Tablet

Introduction

Prasugrel hydrochloride is an antiplatelet medication used to prevent blood clots in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI). It is a thienopyridine derivative and a prodrug that inhibits platelet aggregation.

Uses

Prasugrel hydrochloride is primarily used to:

Prevent cardiovascular events such as heart attack and stroke in patients with acute coronary syndrome (ACS)
Reduce the risk of clot formation during and after percutaneous coronary interventions (PCI), such as stent placement
Improve outcomes in patients undergoing coronary artery bypass grafting (CABG) or similar procedures

Brand Name	Efirel
Type	Tablet
Weight	10 mg
Generic	Prasugrel Hydrochloride
Manufacturer	Opsonin Pharma Ltd.
Available in	English বাংলা

Mechanism of Action

Prasugrel is a prodrug that is metabolized in the liver to its active form. The active metabolite irreversibly binds to the P2Y12 receptor on platelets, inhibiting adenosine diphosphate (ADP) from binding to the receptor. This prevents platelet activation and aggregation, reducing the likelihood of clot formation.

How Long Does It Take to Work?

Prasugrel starts to exert its antiplatelet effects within 30 minutes to 1 hour after ingestion. Peak platelet inhibition typically occurs within 1-2 hours of administration. Full effects are generally observed within 2-4 hours.

Absorption

Prasugrel is well absorbed from the gastrointestinal tract. It undergoes extensive first-pass metabolism in the liver, where it is converted to its active metabolite. The bioavailability of the active form is approximately 40-50% of the administered dose.

Route of Elimination

The active metabolite of prasugrel is primarily eliminated through the liver and excreted via the urine. About 60% of the dose is excreted in the urine, with the remainder being excreted in the feces.

Dosage

Treatment should be initiated with a single 60 mg oral loading dose. Continue at 10 mg once daily with or without food. Consider 5 mg once daily for patients <60 kg. Patients should also take aspirin (75 mg to 325 mg) daily.

The typical dosage of prasugrel is:

Initial dose: 60 mg orally, given as a loading dose
Maintenance dose: 10 mg orally once daily

Dosage may be adjusted based on patient characteristics and clinical response. Lower doses (5 mg daily) are recommended for patients who weigh less than 60 kg or are at high risk for bleeding.

Administration

Prasugrel is administered orally, usually in the form of tablets. It can be taken with or without food. Adherence to prescribed dosages and schedules is important for optimal efficacy.

Side Effects

Common side effects include:

Bleeding complications (e.g., nosebleeds, bruising)
Nausea
Headache

Serious side effects may include:

Severe bleeding or hemorrhage
Thrombocytopenia (low platelet count)
Severe allergic reactions (e.g., rash, swelling, difficulty breathing)

Toxicity

Toxicity can manifest as excessive bleeding or hemorrhage. Symptoms may include:

Prolonged or uncontrolled bleeding
Severe bruising
Signs of internal bleeding (e.g., dark stools, persistent cough with blood)

In case of suspected toxicity, discontinue use and seek immediate medical attention. Treatment may involve supportive care and reversal of antiplatelet effects.

Precautions

Precautions should be taken in individuals with:

History of bleeding disorders or gastrointestinal bleeding
Severe renal or hepatic impairment
Recent surgery or trauma

Regular monitoring and dose adjustments may be necessary based on patient condition and response.

Interaction

Interactions may include:

Other antiplatelet or anticoagulant medications (e.g., aspirin, warfarin)
Drugs affecting liver enzymes (e.g., CYP3A4 and CYP2C19 inhibitors or inducers)
Medications affecting bleeding risk (e.g., NSAIDs)

Monitor for potential interactions and adjust therapy as needed.

Disease Interaction

Prasugrel should be used with caution in patients with:

Chronic kidney disease
Hepatic impairment
Peptic ulcer disease or gastrointestinal bleeding history

Drug Interaction

Drug interactions may include:

Medications that impact platelet function or blood clotting (e.g., clopidogrel, ticagrelor)
Drugs influencing hepatic metabolism (e.g., omeprazole, rifampin)
Other medications with bleeding risk (e.g., selective serotonin reuptake inhibitors)

Food Interactions

Food interactions are minimal, but it is generally advised to avoid excessive intake of foods or beverages that might affect bleeding risk, such as alcohol, which can increase the risk of bleeding.

Pregnancy Use

Prasugrel is classified as a Category B drug for pregnancy, indicating that there are no proven risks to the fetus based on animal studies. However, its use during pregnancy should be limited to situations where the benefits outweigh potential risks. Consult a healthcare provider for personalized advice.

Lactation Use

The use of prasugrel during lactation is not well studied. Caution is advised as the drug may be excreted in breast milk. Consult a healthcare provider to weigh the benefits and risks if use is necessary.

Acute Overdose

Acute overdose of prasugrel may lead to:

Severe bleeding complications
Extended bleeding times
Potential for internal bleeding or hemorrhage

In case of overdose, discontinue use and seek immediate medical attention. Treatment may involve supportive care and measures to reverse bleeding.

Contraindication

Prasugrel is contraindicated in individuals with:

Active bleeding disorders or history of major bleeding
Severe hepatic impairment
Allergy or hypersensitivity to prasugrel

Use Direction

Follow the specific instructions provided by your healthcare provider or product label. Prasugrel is usually taken once daily. It is important to adhere to the prescribed dosage and schedule and to report any side effects or issues to a healthcare provider.

Storage Conditions

Store prasugrel tablets at room temperature, between 15°C and 30°C (59°F and 86°F). Keep in a dry place, protected from light and moisture. Ensure that the medication is kept out of reach of children and not used beyond its expiration date.

Volume of Distribution

The volume of distribution for prasugrel is approximately 80 liters. The drug is extensively distributed in the body tissues, including the platelets where it exerts its antiplatelet effects.

Half Life

The half-life of prasugrel's active metabolite is approximately 7-8 hours. However, the effects on platelet function persist for a longer duration due to the irreversible nature of its binding to the P2Y12 receptor.

Clearance

Prasugrel is primarily cleared through the liver with subsequent excretion via the kidneys. The drug undergoes extensive metabolism and is cleared from the body with a terminal elimination half-life of around 7-8 hours.

See in details version Efirel Tablet 10 mg also Efirel Tablet 10 mg in bangla